Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Tongue Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non-Muscle Invasive Bladder Neoplasms 1Lymphoid Interstitial Pneumonia 1Keratosis, Actinic 1Esophageal Squamous Cell Carcinoma 1Epitheliod Malignant Pleural Mesothelioma 1Carcinoma, Transitional Cell 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 45Paclitaxel 8Cisplatin 8Carboplatin 8lenvatinib 7Pemetrexed 5Gemcitabine 4camrelizumab 3Docetaxel 3Capecitabine 3epacadostat 2avelumab 2Fluorouracil 2Cetuximab 2Acetaminophen 2vicriviroc 1sinoporphyrin sodium 1penpulimab 1olaparib 1etoposide phosphate 1enzalutamide 1balstilimab 1apatinib 1Temozolomide 1Tadalafil 1Standard of Care 1Serotonin 5-HT3 Receptor Antagonists 1Radiotherapy 1Radiosurgery 1Poly(ADP-ribose) Polymerase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Parkinson Disease 4, Autosomal Dominant Lewy Body × 1-phenyl-3,3-dimethyltriazene × Clear all
NCT05386056 2022-11-28

Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

Peking University

Phase 2 Unknown
54 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡